Engel Europe sells bonds

Engel Europe Ltd., an Israeli-based real estate developer focused on Eastern European projects, has announced the issuance of NIS 150 million of bonds that were sold privately to institutional investors.

By RYAN NADEL
October 4, 2006 08:02

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Engel Europe Ltd., an Israeli-based real estate developer focused on Eastern European projects, has announced the issuance of NIS 150 million of bonds that were sold privately to institutional investors. This completes a fundraising effort of NIS 700 million of capital over the last year. The funds will be used to accelerate investments in the international market. Engel Europe is currently involved in the launching of six new eastern European shopping centers.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS